Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company’s milestones achieved in 2025, transformative initiatives, and forward-looking outlook for 2026 and beyond.
Presentation Highlights:
- Pivot to Growth Strategy Progress: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative pipeline, fueled by its world-class generics business.
- Innovation at the Heart of Teva's Transformation: Teva's key innovative brands – AUSTEDO®, AJOVY® and UZEDY® – are already driving its growth and reshaping Teva's financial outlook. Teva’s clinical pipeline assets – olanzapine LAI, DARI (ICS/SABA), duvakitug (anti-TL1A), emrusolmin, and anti-IL-15 – are expected to drive Teva's long-term growth trajectory and further Teva’s transformation.
- 2025 Performance: Teva to provide its expected 2025 financial performance.
- 2026 and Beyond: In addition, Teva to provide forward-looking outlook for 2026 and beyond, underlining disciplined capital allocation and a commitment to securing an investment-grade credit rating.
Expected 2025 Performance
| $ billions, except EPS or as noted | 2025 Outlook | Expected 2025 performance relative to Outlook (excluding duvakitug milestones) | Additional contribution from expected duvakitug milestones |
| Revenues* | $16.8 - $17.0 | Lower point of the range | $500M |
| Operating Margin | ~26.2% - 27.1% | Mid to high point of the range | ~80%-85% |
| Adjusted EBITDA | $4.8 - $5.0 | Midpoint of the range | ~$400M-$430M |
| Tax Rate | 15%-18% | Lower point of the range |
|
| Diluted EPS ($) | 2.55 - 2.65 | Higher point of the range |
|
| Free Cash Flow** | $1.6 - $1.9 | Higher point of the range | ~$500M |
| Net leverage | ~2.5x - 2.9x | Midpoint of the range | ~2.5x |
Path to achieving 2027 targets and additional 2030 targets
| $billionsor as noted | 2026 | 2027 | 2030 |
| Revenues* | Flat to slightly down vs. 2025 | Low-single digit growth | Mid-single digit CAGR |
| Operating Profit | Growing vs. 2025 | 30% | >30% |
| Adjusted EBITDA | Growing vs. 2026 | Growing | |
| Free Cash Flow** | Growing vs. 2025 | >$2.7 | >$3.5 |
| Net Leverage | ~2.0-2.2x | <2x | <2x |
| Cumulative Transformation Programs Savings | ~$450M-500M | ~$700M |
|
Note: 2026 commentary compared to 2025 results excluding duvakitug milestones, except for net debt leverage calculation.
* Revenues presented on a GAAP basis; all other metrics presented on a non-GAAP basis.
** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.
To access a live webcast of the presentation, visit Teva’s Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to better health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
